These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9358333)

  • 21. Ethics and practice: alternative designs for phase III randomized clinical trials.
    Palmer CR; Rosenberger WF
    Control Clin Trials; 1999 Apr; 20(2):172-86. PubMed ID: 10227416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validity of tests under covariate-adaptive biased coin randomization and generalized linear models.
    Shao J; Yu X
    Biometrics; 2013 Dec; 69(4):960-9. PubMed ID: 23848580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomization in substance abuse clinical trials.
    Hedden SL; Woolson RF; Malcolm RJ
    Subst Abuse Treat Prev Policy; 2006 Feb; 1():6. PubMed ID: 16722591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
    Sugimoto T; Sozu T; Hamasaki T; Evans SR
    Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial.
    Yuan Y; Huang X; Liu S
    Stat Med; 2011 May; 30(11):1218-29. PubMed ID: 21432894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
    Howard G; Coffey CS; Cutter GR
    Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
    [No Abstract]   [Full Text] [Related]  

  • 31. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive dose finding based on t-statistic for dose-response trials.
    Ivanova A; Bolognese JA; Perevozskaya I
    Stat Med; 2008 May; 27(10):1581-92. PubMed ID: 18241082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing unequal randomization in clinical trials with heterogeneous treatment costs.
    Sverdlov O; Ryeznik Y
    Stat Med; 2019 Jul; 38(16):2905-2927. PubMed ID: 31049999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive sequential testing for multiple comparisons.
    Gao P; Liu L; Mehta C
    J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subgroup-adaptive randomization for subgroup confirmation in clinical trials.
    Liu Z; Ma X; Wang Z
    Biom J; 2021 Mar; 63(3):616-631. PubMed ID: 33245162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
    Nomura S; Hirakawa A; Hamada C
    J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomization by minimization for unbalanced treatment allocation.
    Han B; Enas NH; McEntegart D
    Stat Med; 2009 Nov; 28(27):3329-46. PubMed ID: 19739238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials.
    Nowacki AS; Zhao W; Palesch YY
    Stat Methods Med Res; 2017 Jun; 26(3):1078-1092. PubMed ID: 25586325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.